

Satoshi Sakai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11978464/publications.pdf>

Version: 2024-02-01

65
papers

3,106
citations

218381

26
h-index

155451

55
g-index

66
all docs

66
docs citations

66
times ranked

2809
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. <i>Nature</i> , 1996, 384, 353-355.	13.7	623
2	Endogenous Endothelin-1 Participates in the Maintenance of Cardiac Function in Rats With Congestive Heart Failure. <i>Circulation</i> , 1996, 93, 1214-1222.	1.6	244
3	Aging-induced decrease in the PPAR- α level in hearts is improved by exercise training. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H1750-H1760.	1.5	159
4	Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-b pathway. <i>Journal of the American College of Cardiology</i> , 2004, 43, 1481-1488.	1.2	158
5	Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure. <i>EMBO Journal</i> , 2004, 23, 3559-3569.	3.5	145
6	Endothelin-1-Induced Cardiac Hypertrophy Is Inhibited by Activation of Peroxisome Proliferator-Activated Receptor- α Partly Via Blockade of c-Jun NH2-Terminal Kinase Pathway. <i>Circulation</i> , 2004, 109, 904-910.	1.6	112
7	Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 281, R2029-R2036.	0.9	111
8	Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. <i>FEBS Letters</i> , 1993, 332, 31-34.	1.3	104
9	Stimulation of peroxisome-proliferator-activated receptor α (PPAR α) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. <i>Clinical Science</i> , 2002, 103, 284S-288S.	1.8	101
10	Role of Endothelin in Deterioration of Heart Failure Due to Cardiomyopathy in Hamsters. <i>Circulation</i> , 1999, 99, 2171-2176.	1.6	98
11	Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. <i>Journal of the American College of Cardiology</i> , 1996, 28, 1580-1588.	1.2	96
12	Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1995, 110, 271-273.	0.4	82
13	The Effect of Bosentan, a New Potent Endothelin Receptor Antagonist, on the Pathogenesis of Cerebral Vasospasm. <i>Neurosurgery</i> , 1995, 37, 87-91.	0.6	70
14	MicroRNA-155 is associated with oral squamous cell carcinoma metastasis and poor prognosis. <i>Journal of Oral Pathology and Medicine</i> , 2016, 45, 248-255.	1.4	69
15	Cardiac Hypertrophy by Hypertension and Exercise Training Exhibits Different Gene Expression of Enzymes in Energy Metabolism. <i>Hypertension Research</i> , 2003, 26, 829-837.	1.5	66
16	Long-Term Endothelin Receptor Antagonist Administration Improves Alterations in Expression of Various Cardiac Genes in Failing Myocardium of Rats With Heart Failure. <i>Circulation</i> , 2000, 101, 2849-2853.	1.6	64
17	Tenascin-C Aggravates Autoimmune Myocarditis via Dendritic Cell Activation and Th17 Cell Differentiation. <i>Journal of the American Heart Association</i> , 2014, 3, e001052.	1.6	64
18	Peroxisome proliferator-activated receptor- α activators inhibit endothelin-1-related cardiac hypertrophy in rats. <i>Clinical Science</i> , 2002, 103, 16S-20S.	1.8	55

#	ARTICLE	IF	CITATIONS
19	Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999, 276, H1197-H1206.	1.5	51
20	Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization. <i>Cardiovascular Research</i> , 2019, 115, 614-624.	1.8	50
21	DOWN-REGULATION OF ET _b RECEPTOR, BUT NOT ET _a RECEPTOR, IN CONGESTIVE LUNG SECONDARY TO HEART FAILURE. ARE MARKED INCREASES IN CIRCULATING ENDOTHELIN-1 PARTLY ATTRIBUTABLE TO DECREASES IN LUNG ET _b RECEPTOR-MEDIATED CLEARANCE OF ENDOTHELIN-1?. <i>Life Sciences</i> , 1997, 62, 185-193.	2.0	47
22	Corresponding distributions of increased endothelin β receptor expression and increased endothelin α expression in the aorta of apolipoprotein E δ deficient mice with advanced atherosclerosis. <i>Pathology International</i> , 2000, 50, 929-936.	0.6	44
23	Endothelin and the heart in health and diseases. <i>Peptides</i> , 2019, 111, 77-88.	1.2	39
24	Activation of Peroxisome Proliferator-activated Receptor- γ Decreases Endothelin-1-induced p38 Mitogen-activated Protein Kinase Activation in Cardiomyocytes. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S358-S361.	0.8	29
25	Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 468-478.	0.3	29
26	Prolonged exercise causes an increase in endothelin-1 production in the heart in rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 275, H2105-H2112.	1.5	27
27	A combination of oral endothelin-receptor antagonist and oral prostacyclinanalogue is superior to each drug alone in ameliorating pulmonary hypertension in rats. <i>Journal of the American College of Cardiology</i> , 2002, 40, 175-181.	1.2	27
28	Calcitonin gene-related peptide protects the myocardium from ischemia induced by endothelin-1: Intravital microscopic observation and 31P-MR spectroscopic studies. <i>Life Sciences</i> , 2014, 118, 248-254.	2.0	25
29	MicroRNA-205-5p suppresses the invasiveness of oral squamous cell carcinoma by inhibiting TIMP α 2 expression. <i>International Journal of Oncology</i> , 2018, 52, 841-850.	1.4	23
30	The benefit of medium-chain triglyceride therapy on the cardiac function of SHR is associated with a reversal of metabolic and signaling alterations. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H136-H144.	1.5	21
31	Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. <i>Circulation Journal</i> , 2017, 81, 1360-1367.	0.7	19
32	Exercise habituation is effective for improvement of periodontal disease status: a prospective intervention study. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 565-574.	0.9	19
33	Endothelin-1 Expression in Hearts of Transgenic Hypertensive Mice Overexpressing Angiotensin II. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S412-S416.	0.8	17
34	Chronic Administration of an Endothelin-A Receptor Antagonist Improves Exercise Capacity in Rats with Myocardial Infarction-induced Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S64-S67.	0.8	16
35	Endothelin-Converting Enzyme and Angiotensin-Converting Enzyme in Failing Hearts of Rats with Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S417-S420.	0.8	16
36	Altered Expression of Isoforms of Myosin Heavy Chain mRNA in the Failing Rat Heart Is Ameliorated by Chronic Treatment with an Endothelin Receptor Antagonist. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S302-S305.	0.8	15

#	ARTICLE	IF	CITATIONS
37	Myocardial expression of endothelin-2 is altered reciprocally to that of endothelin-1 during ischemia of cardiomyocytes in vitro and during heart failure in vivo. <i>Life Sciences</i> , 1999, 65, 1671-1683.	2.0	14
38	Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy. <i>Life Sciences</i> , 2014, 102, 98-104.	2.0	13
39	Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1999, 277, R1321-R1330.	0.9	12
40	Endothelin receptor antagonist exacerbates autoimmune myocarditis in mice. <i>Life Sciences</i> , 2014, 118, 288-296.	2.0	10
41	Effects of selective endothelin (ET)-A receptor antagonist versus dual ET-A/B receptor antagonist on hearts of streptozotocin-treated diabetic rats. <i>Life Sciences</i> , 2014, 111, 6-11.	2.0	10
42	Fish oil constituent eicosapentaenoic acid inhibits endothelin-induced cardiomyocyte hypertrophy via PPAR- α . <i>Life Sciences</i> , 2014, 118, 173-178.	2.0	10
43	Chronic treatment with probucol effectively inhibits progression of pulmonary hypertension in rats. <i>Life Sciences</i> , 2000, 67, 2017-2023.	2.0	9
44	Negative expression of N-acetylglucosaminyltransferase V in oral squamous cell carcinoma correlates with poor prognosis. <i>SpringerPlus</i> , 2013, 2, 657.	1.2	8
45	Bosentan reverses the hypoxia-induced downregulation of the bone morphogenetic protein signaling in pulmonary artery smooth muscle cells. <i>Life Sciences</i> , 2016, 159, 111-115.	2.0	8
46	p62 modulates the intrinsic signaling of UVB-induced apoptosis. <i>Journal of Dermatological Science</i> , 2016, 83, 226-233.	1.0	8
47	The endothelin receptor antagonist ameliorates the hypertensive phenotypes of transgenic hypertensive mice with renin-angiotensin genes and discloses roles of organ specific activation of endothelin system in transgenic mice. <i>Life Sciences</i> , 2004, 74, 1105-1118.	2.0	7
48	YM598, an Orally Active ETA Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-side Heart Failure in Rats with Cor Pulmonale and Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S354-S357.	0.8	7
49	Antagonists to endothelin receptor type B promote apoptosis in human pulmonary arterial smooth muscle cells. <i>Life Sciences</i> , 2016, 159, 116-120.	2.0	7
50	Generation of Transgenic Mice that Conditionally Overexpress Tenascin-C. <i>Frontiers in Immunology</i> , 2021, 12, 620541.	2.2	7
51	Endothelin-1-induced cardiomyocyte hypertrophy is partly regulated by transcription factor II-F interacting C-terminal domain phosphatase of RNA polymerase II. <i>Life Sciences</i> , 2012, 91, 572-577.	2.0	6
52	Clinical value of plasma pentraxin 3 levels for predicting cardiac troponin elevation after percutaneous coronary intervention. <i>Life Sciences</i> , 2014, 95, 40-44.	2.0	6
53	Cloning of Hamster Preproendothelin-1 cDNA and Its Expression in the Heart. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S298-S301.	0.8	6
54	Distribution of endothelin-1 in the lung of rats with pulmonary hypertension of different etiology. <i>International Journal of Angiology</i> , 1998, 7, 160-164.	0.2	5

#	ARTICLE	IF	CITATIONS
55	Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients. <i>Current Medical Research and Opinion</i> , 2020, 36, 921-928.	0.9	4
56	Potential of Gold Nanoparticles for Noninvasive Imaging and Therapy for Vascular Inflammation. <i>Molecular Imaging and Biology</i> , 2022, 24, 692-699.	1.3	3
57	Endothelin-1 in the Heart During Exercise. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S392-S394.	0.8	3
58	Mechanisms explaining the late "catch-up" phenomenon after sirolimus-eluting stent implantation. <i>International Journal of Cardiology</i> , 2014, 177, 44-45.	0.8	2
59	Endothelin-1 and Right-sided Heart Failure in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S327-S330.	0.8	1
60	Hypotensive Effect of Endothelin-1 via Endothelin-B-Receptor Pathway on Pulmonary Circulation is Enhanced in Rats with Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S95-S98.	0.8	1
61	The effectiveness of upfront pulmonary vasodilators combination therapy in addition to corticosteroids for pulmonary arterial hypertension associated with systemic lupus erythematosus: two successful cases utilising both corticosteroids and an upfront combination of vasodilators. <i>Modern Rheumatology Case Reports</i> , 2017, 1, 73-78.	0.3	1
62	Abstract 13566: Pitavastatin Regulates mTOR Complex 1 Signaling Through Inhibition of Rheb in T Cells. <i>Circulation</i> , 2014, 130, .	1.6	1
63	Endothelin-A-Receptor Antagonist and Oral Prostacyclin Analog are Comparably Effective in Ameliorating Pulmonary Hypertension and Right Ventricular Hypertrophy in Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2000, 36, S305-S310.	0.8	0
64	Abstract 13522: Vascular Healing in Drug-Eluting Stents: Differential Response of Limus-Eluting Stents in a Preclinical Model of Stent Implantation. <i>Circulation</i> , 2014, 130, .	1.6	0
65	Abstract 533: Gold Nanoparticles Allow CT Imaging of Experimental Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	1.1	0